ReviewWorld journal of nephrology2013
Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.
Review in World journal of nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Pregnancy-Associated Thrombotic Thrombocytopenic Purpura: Diagnostic Pitfalls, Therapeutic Strategies, and Emerging Paradigms.Biomedicines · 2026Review
- Incidentally detected bilateral sub-internal limiting membrane hemorrhages in typical hemolytic uremic syndrome: a case report.Childhood kidney diseases · 2025Article
- The outcome of thrombotic microangiopathy in kidney transplant recipients.BMC nephrology · 2024Article
- The Role of the Complement System in the Pathogenesis of Infectious Forms of Hemolytic Uremic Syndrome.Biomolecules · 2023Review
- Haemolytic uraemic syndrome managed with subtotal colectomy.BMJ case reports · 2023Article
- Hemolytic uremic syndrome with central nervous system manifestations, a case report and literature review.Radiology case reports · 2023Article
- Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome.Obstetric medicine · 2023Article
- Propensity score-matched analysis of long-term outcomes for living kidney donation in alternative complement pathway diseases: a pilot study.Journal of nephrology · 2023Article
- Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy.The American journal of case reports · 2022Article
- EnterohemorrhagicInternational journal of molecular sciences · 2022Review
- Development and pilot implementation of Iranian Hemolytic Uremic Syndrome Registry.Orphanet journal of rare diseases · 2022Article
- Article
- Hemolytic Uremic Syndrome in Children.Turkish archives of pediatrics · 2021Article
- Influenza-associated hemolytic uremic syndrome: The pathogenic role of the virus.Clinical nephrology. Case studies · 2021Article
- A unique case of hemolytic-uremic syndrome secondary to enteropathogenicClinical case reports · 2020Article
- A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases.Pharmaceutical medicine · 2020Article
- Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem.International journal of molecular sciences · 2020Review
- Article
- Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients.Annals of transplantation · 2018Article
- Genetic Susceptibility to Postdiarrheal Hemolytic-Uremic Syndrome After Shiga Toxin-Producing Escherichia coli Infection: A Centers for Disease Control and Prevention FoodNet Study.The Journal of infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemolytic uremic syndrome (HUS) is a rare disease. In this work the authors review the recent findings on HUS, considering the different etiologic and pathogenetic classifications. New findings in genetics and, in particular, mutations of genes that encode the complement-regulatory proteins have improved our understanding of atypical HUS. Similarly, the complement proteins are clearly involved in all types of thrombotic microangiopathy: typical HUS, atypical HUS and thrombotic thrombocytopenic purpura (TTP). Furthermore, several secondary HUS appear to be related to abnormalities in complement genes in predisposed patients. The authors highlight the therapeutic aspects of this rare disease, examining both "traditional therapy" (including plasma therapy, kidney and kidney-liver transplantation) and "new therapies". The latter include anti-Shiga-toxin antibodies and anti-C5 monoclonal antibody "eculizumab". Eculizumab has been recently launched for the treatment of the atypical HUS, but it appears to be effective in the treatment of typical HUS and in TTP. Future therapies are in phases I and II. They include anti-C5 antibodies, which are more purified, less immunogenic and absorbed orally and, anti-C3 antibodies, which are more powerful, but potentially less safe. Additionally, infusions of recombinant complement-regulatory proteins are a potential future therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.